A clinical trial notification for Telomelysin for laryngeal and pharyngeal cancer Phase 2 was submitted to the PMDA. Dosing is planned to start in the first half of 2027. The new indication aims to preserve vocal cord function. The company states the impact on fiscal 2026 year-end financials is minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4588-20261110-01.pdf","jir_short_summary":"A clinical trial notification for Telomelysin for laryngeal and pharyngeal cancer Phase 2 was submitted to the PMDA. Dosing is planned to start in the first half of 2027. The new indication aims to preserve vocal cord function. The company states the impact on fiscal 2026 year-end financials is minimal.","jir_summary":"### Clinical Trial Notification Submission and Development Policy\nOncolys BioPharma Inc. has submitted a clinical trial notification to the PMDA for a Phase 2 clinical trial of Telomelysin (development code: OBP-301), an oncolytic virus, for a new indication targeting laryngeal and pharyngeal cancer. The company plans to establish a clinical trial network centered on research groups and aims to begin dosing in the first half of 2027.\n\n### Target Patients and Treatment Policy\nThe trial is a pilot study evaluating the efficacy and safety of concurrent radiotherapy and Telomelysin administration, targeting patients who are not candidates for surgical resection or chemoradiotherapy or who decline those options. The development concept emphasizes preservation of laryngeal and pharyngeal function under a new 'vocal cord preservation' strategy.","jir_financial_highlights":"Impact on Financial Results: Unknown (Unknown)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #ClinicalTrialNotification","jir_key_figures":"Clinical trial notification submission: Submitted to PMDA\nPlanned start of dosing: First half of 2027\nTarget indication: Laryngeal and pharyngeal cancer","jir_meta_title":"Oncolys BioPharma Inc. Announces Clinical Trial Notification Submission for Laryngeal and Pharyngeal Cancer\uff5cNovember 2026","jir_meta_description":"Oncolys BioPharma Inc. has submitted a clinical trial notification for Telomelysin for laryngeal and pharyngeal cancer. Dosing is planned to begin in the first half of 2027. Details on the new development policy aiming for vocal cord preservation.","jir_og_title":"Oncolys BioPharma Inc. Announces Submission of Clinical Trial Notification for Laryngeal and Pharyngeal Cancer","jir_og_description":"A Phase 2 clinical trial notification for Telomelysin as a new indication for laryngeal and pharyngeal cancer has been submitted. Dosing is planned from the first half of 2027. A new strategy aiming to preserve vocal cord function.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-145843","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n